Please use this identifier to cite or link to this item: https://doi.org/10.21256/zhaw-1692
Publication type: Article in scientific journal
Type of review: Peer review (publication)
Title: Development of a non-hydroxamate dual matrix metalloproteinase (MMP)-7/-13 inhibitor
Authors : Fischer, Thomas
Riedl, Rainer
DOI : 10.21256/zhaw-1692
10.3390/molecules22091548
Published in : Molecules
Volume(Issue) : 22
Issue : 9
Issue Date: 2017
Publisher / Ed. Institution : MDPI
ISSN: 1420-3049
1433-1373
Language : English
Subjects : Medicinal chemistry; Drug discovery; Inhibitor
Subject (DDC) : 615: Pharmacology and therapeutics
Abstract: Matrix metalloproteinase 7 (MMP-7) is a member of the MMP superfamily and is able to degrade extracellular matrix proteins such as casein, gelatin, fibronectin and proteoglycan. MMP-7 is a validated target for the development of small molecule drugs against cancer. MMP-13 is within the enzyme class the most efficient contributor to type II collagen degeneration and is a validated target in arthritis and cancer. We have developed the dual MMP-7/-13 inhibitor ZHAWOC6941 with IC50-values of 2.2 M (MMP-7) and 1.2 M (MMP-13) that is selective over a broad range of MMP isoforms. It spares MMP-1, -2, -3, -8, -9, -12 and -14, making it a valuable modulator for targeted polypharmacology approaches.
URI: https://digitalcollection.zhaw.ch/handle/11475/2895
Fulltext version : Published version
License (according to publishing contract) : CC BY 4.0: Attribution 4.0 International
Departement: Life Sciences and Facility Management
Appears in Collections:Publikationen Life Sciences und Facility Management

Files in This Item:
File Description SizeFormat 
2017_Fischer_Development of a non-hydroxamate dual matrix metalloproteinase_Molecules.pdf1.83 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.